Fertitta in exclusive talks to buy Caesars for $7bn, tops Icahn

Billionaire Tilman Fertitta’s Fertitta Entertainment has been reported to be in exclusive talks to acquire Caesars Entertainment for roughly $7 billion, outpacing a competing approach from Carl Icahn’s investment vehicle. Sources caution that no definitive agreement has been reached and an announcement is not imminent.

According to published reports, the discussions have centered on a per-share figure in the mid-30s—around $34—while Icahn-related offers were reported near $33 per share. Insiders and people familiar with the matter emphasize that negotiations remain fluid and could still fail to produce a transaction; Caesars and the bidders have not publicly confirmed terms.

Markets reacted to the takeover chatter as investors priced in a potential control premium and strategic reset. Caesars shares rose on the news and trading activity picked up as market participants weighed the implications of a private buyer taking control and the potential for balance-sheet restructuring. Reports note that the company's market valuation is meaningfully below the headline takeover figure, reflecting both equity and liabilities.

Dealmakers and analysts highlight material execution risks: Caesars’ elevated debt load, the need for sizeable financing commitments and state-level regulatory approvals for casino and sports-betting operations complicate a swift close. Some coverage also notes that operational factors—particularly sportsbook revenue timing tied to major sports seasons—make a near-term closing unlikely, with the 2026-27 season cited as the earliest period where a change of control would have practical impact.

Market watchers say the coming weeks should bring clarity on whether exclusive talks progress to a definitive agreement, whether Icahn pushes a rival path and how financing would be structured. Until parties issue formal statements or file required disclosures, analysts advise treating talks as contingent and subject to significant due diligence, regulatory review and possible competitive counterproposals.